drug
Clobetasol Propionate Teva
Marketedupdated 3mo agoby Teva Pharmaceuticals USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 12 investigational indications.
indications
investigational
Psoriasis
all catalysts(1)
Trials studying Clobetasol Propionate Teva
- phase1A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)
- phase1A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin
- phase1A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris
- phase1A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin
- phase3Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 4, 2027
198 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- May 9, 2036formulationUS 10588913
- May 9, 2036formulationUS 11376262
- Mar 11, 2035formulationUS 9855334
- Aug 31, 2030formulationUS 100648754.0y
- Aug 31, 2030formulationUS 105889144.0y
- Aug 31, 2030formulationUS 111794654.0y
- Aug 31, 2030formulationUS 99562314.0y
- Nov 5, 2028formulationUS 84606412.2y
FDA exclusivities (1)
- Mar 4, 2027NPNP198d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that